Product Data Sheet

3-Mercaptopropionic acid NHS ester

Cat. No.: HY-136159 CAS No.: 117235-10-6 Molecular Formula: $C_7H_0NO_4S$ Molecular Weight: 203.22

Target: **PROTAC Linkers**

Pathway: **PROTAC**

Storage: Pure form -20°C 3 years

2 years

In solvent -80°C 6 months

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (492.08 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|------------|------------|
| | 1 mM | 4.9208 mL | 24.6039 mL | 49.2078 mL |
| | 5 mM | 0.9842 mL | 4.9208 mL | 9.8416 mL |
| | 10 mM | 0.4921 mL | 2.4604 mL | 4.9208 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (12.30 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (12.30 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (12.30 mM); Clear solution

BIOLOGICAL ACTIVITY

| Description | 3-Mercaptopropanyl-N-hydroxysuccinimide ester is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs ^[1] . | |
|---------------------------|--|--|
| IC ₅₀ & Target | Alkyl/ether | |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . | |

| | MCL has not independe | intry commined the accuracy c | of these methods. They are for referen | ice only. |
|-------------------------------|------------------------------|---------------------------------|---|--------------------------------|
| | | | | |
| DEEEDENCES | | | | |
| REFERENCES | | | | |
| 1]. An S, et al. Small-molect | ule PROTACs: An emerging and | d promising approach for the de | velopment of targeted therapy drugs. EB | oMedicine. 2018 Oct;36:553-562 |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | medical applications. For research us | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpre | ss.com |
| | Address: | 1 Deer Park Dr, Suite Q, Monr | mouth Junction, NJ 08852, USA | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Page 2 of 2 www.MedChemExpress.com